King's College London

Research portal

Safely targeting autoimmunity in type 1 diabetes: The MonoPepT1De trial

Research output: Contribution to journalArticlepeer-review

Yuk Fun Liu, Mark Peakman, Colin M. Dayan

Original languageEnglish
Pages (from-to)148-150a
Number of pages4
JournalPractical Diabetes
Issue number4
Published1 May 2013

King's Authors


PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454